XOMA Royalty Corporation announced that Zevra Therapeutics received FDA approval for MIPLYFFA, a treatment for Niemann-Pick disease, and XOMA has a royalty agreement that includes a $5 million upfront payment and potential milestone payments of up to $52.6 million.